Posted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for three patient populations.
The patient populations are:
- Patients who, despite basic treatment with statins and ezetimibe, have not reached their target values for LDL cholesterol and who have contracted cardiovascular disease as a result
- Patients who have high LDL cholesterol due to genetic causes
- Patients with high LDL cholesterol and very high risk of cardiovascular disease
